Lahiri K K, Sahni A K, Gupta R M, Duhan S D, Kapila K, Jena J
Associate Professor, Armed Forces Medical College, Pune.
Senior Advisor (Microbiology), Base Hospital Delhi Cantt.
Med J Armed Forces India. 2007 Oct;63(4):318-21. doi: 10.1016/S0377-1237(07)80004-9. Epub 2011 Jul 21.
Hepatitis B e antigen negative chronic hepatitis (e(-) CHB) with detectable levels of hepatitis B virus DNA (HBV DNA) in serum has been reported in cases from Asia. This study was undertaken to find out prevalence e(-)CHB and to correlate its presence with the clinical status and severity of the illness in cases of chronic liver disease in India.
All patients of infective hepatitis, who were hepatitis B surface antigen (HBsAg) positive by enzyme-linked immunosorbent assay (ELISA), were evaluated with liver function tests and HBeAg and antiHBe antibody studies. Polymerase chain reaction (PCR) test was carried out to detect HBV DNA qualitatively.
Out of 2064 samples tested by ELISA, 429 (20.78 %) were HBsAg positive. HBV DNA (qualitative) was performed on all 429 patients and 74 (17.2%) were HBV DNA positive. Of these only 42 (56.75 %) tested positive for HBeAg. Overall, 8.3 % of HBeAg negative patients (32/384) were viraemic with evidence of chronic liver disease/clinical cirrhosis and alteration of transaminase levels, while three cases (0.84 %) HBeAg positive cases did not show presence of HBV DNA.
This study shows e(-)CHB prevalence rate of 8.3% in patients with HBV infection in India. Since HBeAg negative patients had detectable levels of HBV DNA as seen in HBeAg positive patients, benefit of antiviral therapy should be given to them. Population studies on e(-) CHB cases are needed to determine its true prevalence, natural course and response to therapy.
在亚洲的病例报告中,出现了血清中可检测到乙肝病毒脱氧核糖核酸(HBV DNA)水平的乙肝e抗原阴性慢性肝炎(e(-)CHB)。本研究旨在查明印度慢性肝病病例中e(-)CHB的患病率,并将其存在情况与疾病的临床状况和严重程度相关联。
所有通过酶联免疫吸附测定(ELISA)检测为乙肝表面抗原(HBsAg)阳性的感染性肝炎患者,均接受肝功能检查、HBeAg和抗HBe抗体研究评估。进行聚合酶链反应(PCR)检测以定性检测HBV DNA。
在通过ELISA检测的2064份样本中,429份(20.78%)为HBsAg阳性。对所有429名患者进行了HBV DNA(定性)检测,其中74名(17.2%)为HBV DNA阳性。在这些患者中,仅42名(56.75%)HBeAg检测呈阳性。总体而言,8.3%的HBeAg阴性患者(32/384)存在病毒血症,伴有慢性肝病/临床肝硬化证据以及转氨酶水平改变,而3例(0.84%)HBeAg阳性病例未显示HBV DNA存在。
本研究表明,印度HBV感染患者中e(-)CHB患病率为8.3%。由于HBeAg阴性患者与HBeAg阳性患者一样,其HBV DNA水平可检测到,因此应给予他们抗病毒治疗。需要对e(-)CHB病例进行人群研究,以确定其真实患病率、自然病程和治疗反应。